Intellia Therapeutics Inc buy Truist Financial Co.
Start price
10.11.25
/
50%
€8.65
Target price
10.11.26
€12.11
Performance (%)
-17.49%
Price
21.11.25
€7.13
Summary
This prediction is currently active. The prediction for Intellia Therapeutics Inc disappoints with a performance of -17.49%. This prediction currently runs until 10.11.26. The prediction end date can be changed by Truist_Financial_Co_ at any time. Truist_Financial_Co_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w |
|---|---|
| Intellia Therapeutics Inc | -4.651% |
| iShares Core DAX® | -2.673% |
| iShares Nasdaq 100 | -2.173% |
| iShares Nikkei 225® | -3.367% |
| iShares S&P 500 | -1.015% |
Comments by Truist_Financial_Co_ for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics (NASDAQ:NTLA) had its "buy" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $14.00 price target on the stock, down previously from $25.00.
Ratings data for NTLA provided by MarketBeat
Stopped prediction by Truist_Financial_Co_ for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€8.43
04.03.25
04.03.25
€47.44
04.03.26
04.03.26
-15.39%
21.11.25
21.11.25
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€23.43
24.06.24
24.06.24
€111.85
24.06.25
24.06.25
-64.98%
25.06.25
25.06.25